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Abstract
Background: With the developments of DNA sequencing technology, large amounts of sequencing data have
become available in recent years and provide unprecedented opportunities for advanced association studies
between somatic point mutations and cancer types/subtypes, which may contribute to more accurate somatic
point mutation based cancer classification (SMCC). However in existing SMCC methods, issues like high data
sparsity, small volume of sample size, and the application of simple linear classifiers, are major obstacles in
improving the classification performance.
Results: To address the obstacles in existing SMCC studies, we propose DeepGene, an advanced deep neural
network (DNN) based classifier, that consists of three steps: firstly, the clustered gene filtering (CGF) concentrates
the gene data by mutation occurrence frequency, filtering out the majority of irrelevant genes; secondly, the
indexed sparsity reduction (ISR) converts the gene data into indexes of its non-zero elements, thereby significantly
suppressing the impact of data sparsity; finally, the data after CGF and ISR is fed into a DNN classifier, which extracts
high-level features for accurate classification. Experimental results on our curated TCGA-DeepGene dataset, which is a
reformulated subset of the TCGA dataset containing 12 selected types of cancer, show that CGF, ISR and DNN all
contribute in improving the overall classification performance. We further compare DeepGene with three widely adopted
classifiers and demonstrate that DeepGene has at least 24% performance improvement in terms of testing accuracy.
Conclusions: Based on deep learning and somatic point mutation data, we devise DeepGene, an advanced cancer type
classifier, which addresses the obstacles in existing SMCC studies. Experiments indicate that DeepGene outperforms three
widely adopted existing classifiers, which is mainly attributed to its deep learning module that is able to extract the high
level features between combinatorial somatic point mutations and cancer types.
Background
Cancer is known as a category of disease causing ab-
normal cell growths or tumors that potentially invade
or metastasize to other parts of human body [1]. It has
long become one of the major lethal diseases which
leads to about 8.2 million, or 14.6%, of all human
deaths each year [2].
To alleviate the impact of cancer to human health,
considerable research endeavors have been devoted to
the related diagnosis and therapy techniques, among
which somatic point mutation based cancer classification
(SMCC) is an important perspective. The purpose of
SMCC is to detect the cancer types or subtypes based
on somatic gene mutations from the patient, so that the
cancer condition of the patient can be specified. Due to
the drop in the cost of DNA sequencing in recent years,
the availability of DNA sequencing data has increased
dramatically, which greatly promotes the developments
of SMCC [3]. Compared with conventional cancer
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classification methods that are mostly based on morpho-
logical appearances or gene expressions of the tumor,
SMCC is particularly effective in differentiating tumors
with similar histopathological appearances [4] and is sig-
nificantly more robust to environmental influences, thus
is favorable in delivering more accurate classification re-
sults. Other genetic aberrations such as copy number
variance, translocation, and small insertion or deletion
have also been shown to be associated with different
cancers [5, 6], but due to the major causal role of som-
atic point mutations and potential application consider-
ation, we only focus on this kind of genetic aberration in
this study. Moreover, the combinatorial point mutation
patterns learned in predicting cancer types/subtypes can
be used for developing diagnostic gene marker panels
that are cost effective. This is particularly true , when
compared to DNA amplifications and rearrangements
which usually require whole genome sequencing and is
expensive for patients, especially regarding time series
and whole genome sequencing used in tracing tumor
linage evolution during cancer progression.
Clinically, SMCC may significantly facilitate cancer-
related diagnoses and treatments, such as personalized
tumor medicine [7], targeted tumor therapy [8] and
compound medicine [9]. It can also aid cancer early
diagnosis (CED) in combination with the sampling and
sequencing of circulating tumor cells (CTCs) or circu-
lating DNA (ctDNA) [10–12]. Given the promising
applications above, SMCC is widely studied in recent
researches [13–15].
In recent years, the drastic developments of machine
learning methods have greatly facilitated the researches
in bioinformatics, including SMCC. In order to predict
the cancer types/subtypes more effectively, many ma-
chine learning approaches have been applied in existing
cancer type prediction works, which have shown prom-
ising results [16–18]. Currently, remarkable develop-
ments have been demonstrated in tumor cases of
colorectal [19], breast [20], ovary [21], brain [22], and
melanoma [23]. However, there are at least three major
unresolved challenges:
(1)Normal sequencing results involve extremely large
number of genes, usually in tens of thousands, but
only a small discriminatory subset of genes is related
to the cancer classification task. The other genes are
largely irrelevant genes whose existence will only
obstruct the cancer classification. Many recent
works have been conducted in identifying the
discriminatory subset of genes. For example, Cho
et al. [24] apply the mean and standard deviation of
the distances from each sample to the class center as
criteria for classification; Yang et al. [25] improve
the method in [24] and bring inter-class variations
into the algorithm; Cai et al. [26] propose the clus-
tered gene selection, which groups the genes via k-
means clustering and picks up the top genes in each
group that are closest to the centroid locations.
These methods are simple and effective in some
cases, but their heuristics are designed for continu-
ous gene expression data, and are not directly
applicable to discrete, and especially binary point
mutation data.
(2)Even within the discriminatory subset, the majority
of genes are not guaranteed to contain informative
point mutations and often remain normal (i.e. zero
values in the data) [27], which results in extremely
sparse gene data (even all-zeros) that is difficult to
classify. Yet, to the best of our knowledge, there has
been no existing work specifically devised for redu-
cing the data sparsity for SMCC.
(3)Different genes related to specific types of cancer are
generally correlated and have complex interactions
which may impede the application of conventional
simple linear classifiers such as linear kernel support
vector machine (SVM) [28]. Therefore, an advanced
classifier being capable of extracting the high level
features within the discriminatory subset is desired.
Although there have been recent works utilizing
sparse-coding [29] or auto-encoder [17] for gene an-
notation, no work has been devoted in applying
high-level machine learning approaches to SMCC.
In recent years, the developments of deep neural net-
work (DNN) [30] have equipped bioinformaticians with
powerful machine learning tools. DNN is a type of artifi-
cial neural network that aims to model abstracted high-
level data features using multiple nonlinear and complex
processing layers, and provides feedback via back-
propagation [31]. First introduced in 1989 [32], DNN has
garnered tremendous developments and is widely applied
in image classification [33, 34], object localization [35, 36],
facial recognition [37, 38], etc. DNN has the potential to
introduce novel opportunities for SMCC where it per-
fectly fits the need for large scale data processing and high
level feature extraction. However, to the present, applying
customized DNN on SMCC is yet to be explored.
In this paper, we propose a novel SMCC method,
named DeepGene, designed to simultaneously address
the three identified issues. DeepGene is a DNN-based
classification model composed of three steps. It first
conducts two pre-processing techniques, including the
clustered gene filtering (CGF) based on mutation occur-
rence frequency, and the indexed sparsity reduction
(ISR) based on indexes of non-zero elements; the gene
data is then classified by a fully-connected DNN classi-
fier into a specific cancer type. The proposed DeepGene
model has four distinct contributions:
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(1)The proposed CGF procedure locates the
discriminatory gene subset based on mutation
occurrence frequency. CGF utilizes features from the
whole dataset instead of the current sample alone
(e.g. mean and standard deviation), and thus more
objectively reflects the correlations among the genes
which can more effectively summarize the
discriminatory subset. In addition, CGF does not
require any prior knowledge from the original data
and therefore functions well on both discrete and
binary point mutation data.
(2)The proposed ISR procedure converts the sparse
gene data into indexes of its non-zero elements. ISR
eliminates the vast majority of zero gene elements,
and significantly reduces the complexity of the gene
data during such process.
(3)We establish a fully connected DNN classifier that
uses the gene data after CGF and ISR for cancer
classification. With the capacity of high-level feature
extraction, our classifier is able to effectively extract
deep features from the complexly correlated gene
data, and significantly improve the classification ac-
curacy compared with conventional simple linear
classifiers such as SVM.
(4)We compile and release the TCGA-DeepGene data-
set, which is a reformulated subset of the widely ap-
plied TCGA dataset [39] in genome-related
researches. TCGA-DeepGene selects 22,834 genes of
12 types of cancer from 3122 different samples, and
regularizes the data in a unified format so that classi-
fication tasks can be readily performed.
The flowchart of DeepGene is shown in Fig. 1. We
conduct experiments on the proposed TCGA-DeepGene
dataset, and DeepGene is evaluated against three widely
adopted classification methods for SMCC. The results
demonstrate that DeepGene has generated significantly
higher performance in terms of testing accuracy against
the comparison methods.
Methods
DeepGene has three major steps, namely clustered gene
filtering (CGF), indexed sparsity reduction (ISR), and
DNN-based classification. The CGF and ISR are two in-
dependent pre-processing modules, the results of which
are then concatenated in the final DNN classifier.
Clustered gene filtering
The CGF step is based on the mutation occurrence fre-
quency of the gene data, and its workflow is summarized
in Table 1. Let A ∈ {0, 1}m × n be the matrix of raw data
with binary value, where the n columns correspond to
the n samples (cases) in the dataset, and the m rows cor-
respond to the m genes per sample. The binary value in-
dicates whether a mutation is observed:
A i; jð Þ ¼ 1
0

if mutation obsereved at gene i of sample j
otherwise
:
We first sum A by row, and concatenate the result with










Since the genes with higher occurrence frequency are
of more interest, the rows of Asum are sorted in descend-
ing order by the second column as Asum
* . After that, we
only keep its index column:
Asum ¼ Asum :; 1ð Þ:
The next step is to group Asum
* by inter-gene similarity
(step 3 in Table 1). For two 1 × n gene samples p and q,
we use the Jaccard coefficient as their inter-sample simi-
larity d(p, q):
d p; qð Þ ¼ sum pqð Þ
sum pjqð Þ ;
where “&” and “|” stand for logical AND and OR.
Fig. 1 Flowchart of the proposed DeepGene method. The raw gene data is first pre-processed by the clustered gene filtering (CGF) and the
indexed sparsity reduction (ISR), respectively, and then fed into the DNN classifier. The output label from the DNN indicates the cancer type of
the input gene sample
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Starting from Asum
* (1), which stands for the index of
the gene with the highest occurrence frequency, we cal-
culate its similarity with each of the following genes. If
their similarity is larger than a predefined threshold
dCGF, the latter gene is merged into the group of Asum
* (1).
After the loop for Asum
* (1), we conduct the loop for the
next ungrouped element in Asum
* , until all the genes are
grouped with a unique group ID.
The final step is to filter the elements from each group
and form the discriminatory subset. We do this by
selecting the top nCGF genes in each group with the
highest mutation occurrence frequency, where nCGF is
another predefined threshold. Groups that have fewer
than nCGF elements are discarded. All of the selected
genes are then united as the result of CGF (steps 5 and
6 in Table 1).
Indexed sparsity reduction
Although the CGF can effectively locate the discrimin-
atory gene subset and filter out the majority of irrelevant
genes, it is still probable that the selected gene subset
being highly sparse, i.e. most of the elements in ACGF are
zeros. The high sparsity is likely to obscure any distin-
guishable feature in the gene data and severely hinder
the classification. Hence, an effective process in reducing
the gene data sparsity is highly desired.
To address the data sparsity issue, we propose the
indexed sparsity reduction (ISR) procedure, which min-
ifies the sparsity by converting the gene data into the in-
dexes of its non-zero genes. For a 1 × n gene sample
p ∈ {0, 1}1 × n, let the number of its non-zero element be
nNZ. We set a pre-defined threshold nISR. If nNZ ≥ nISR,
find the indexes of its top nISR non-zero elements that
have the highest occurrence frequency in Asum
* of the
previous section, and these nISR indexes are listed in as-
cending order as a vector pISR, which is the output of
ISR; if nNZ < nISR, we conduct zero-padding to the tail of
pISR to make it has the length of nISR. The workflow of
ISR is illustrated in Fig. 2.
The significance of ISR is apparent. For each gene
sample p, ISR filters out the majority of its zero elements
and leaves most (if nNZ ≥ nISR) or all (if nNZ < nISR) of its
non-zero elements. Since nISR≪ length(p), the percent-
age of zero elements will drop dramatically after ISR,
which means the impact of data sparsity will be signifi-
cantly suppressed.
DNN-based classifier
As introduced in the previous two sections, both CGF
and ISR have their own advantages when conducted
alone. However, the performance can be even higher if
they are combined together (see more details in the
“Evaluate the effect of combining CGF and ISR” Sec-
tion). We thus combine both CGF and ISR as the pre-
processing for our DNN-based classifier.
As shown in Fig. 1, the raw gene data is processed by
CGF and ISR, separately, and then concatenated as the
input of the DNN classifier. The concatenation is con-
ducted by appending the output of ISR to the tail of the
output of CGF, by which the two outputs form a new
and longer data vector. The classifier is a feed-forward
artificial neural network with fixed input and output
size, and multiple hidden layers for data processing. For
a hidden layer l, its activation (or output value to the
next layer) is computed as:
xl ¼ f zl−1ð Þ;
where f is the activation function, zl is the total weighted
sum of the input:
zl ¼ Wlxl þ bl;
where Wl and bl are the weight matrix and bias vector of
layer l (to be learned in training). In our case, we adopt
the ReLU [40] function as f, and x1 is the input gene
data after pre-processing. The size of the last layer L’s
output xL equals to the number of cancer types ncancer
(ncancer = 12 in our case). xL is then processed by a soft-






where yi ∈ {0, 1} is the ground truth label of cancer type
i, and
Pi ¼ xL ið ÞX
j
exp xL jð Þð Þ
is the softmax probability of cancer type i.
Table 1 Workflow of Clustered Gene Filtering (CGF)
Input: Gene data matrix A ∈ {0, 1}m × n, distance threshold dCGF, group
element threshold nCGF.
1: Sum A by row and sort the result in descent order, and then obtain
the sorted index Asum
* ;
2: Initialize each element as ungrouped;
3: For each ungrouped element i in Asum
* :
(a) For each ungrouped element j in Asum
* other than i:
i. Calculate the similarity d(A(i, :), A(j, :));
ii. If d(A(i, :), A(j, :)) > dCGF, assign j into the group of i;
4: Set the output gene index set gout =∅;
5: For each group c of A after step 3:
(a) If group element number nc≥ nCGF, select the top nCGF genes with
the highest mutation occurrence frequency as gc;
(b) gout = gout ∪ gc;
6: Apply the index set gout on A and get the filtered gene data
ACGF = A(gout, :);
Output: ACGF, i.e. the gene data after CGF
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In training, the loss J is transferred from the last layer
to the former layers via back-propagation [32], by which
the parameters W and b of each layer are updated. The
training then enters the next epoch, and the feed-
forwarding and back-propagation are conducted again.
The training stops when a pre-defined epoch number is
reached. In testing, only the feed-forwarding is con-
ducted (for once) for a testing sample, and the type of
cancer i corresponding to the largest softmax probability
of Pi is adopted as the classification result. The workflow
of the DNN classifier is summarized in Table 2, and the




Our experiments are all conducted on the newly proposed
TCGA-DeepGene dataset, which is a re-formulated subset
of The Cancer Genome Atlas (TCGA) dataset [39] that is
widely applied in genomic researches.
The TCGA-DeepGene subset is formulated by assem-
bling the genes that contain somatic point mutation on
each of the 12 selected types of cancer. Detailed sample
and point mutation statistics for each cancer type can be
found in Table 3. The data is collected from the TCGA
database with filter criteria IlluminaGA_DNASeq_Curated
updated before April, 2015. The mutation information for a
gene is represented by a binary value according to one or
more mutation(s) (1) or without mutation (0) on that gene
for a specific sample. We assemble a total of 22,834 genes
from the 3122 samples, and generate a 22, 834 × 3, 122 bin-
ary data matrix (i.e. the original data matrix A). This data
matrix is the product of our proposed TCGA-DeepGene
subset, where each sample (column) is assigned one of the
labels {1, 2, …, 12} meaning the 12 types of cancer above.
To facilitate the 10-fold cross validation in the follow-
ing experiments, we randomly divide the samples in
each of the 12 cancer categories into 10 subgroups, and
each time we union one subgroup from each cancer cat-
egory as the validation set, while all the other subgroups
are combined as the training set. This formulates 10
training/validation configurations with fair distributions
of the 12 types of cancer, and will be used for the 10-
fold cross validation in our following experiments.
Constant parameters
For the proposed DNN classifier, the output size is set to
12 (i.e. the 12 types of cancer to be classified); the total
training epoch Emax is set to 50; the learning rate is set
to 50-point logarithm space between 10− 1 and 10− 4; the
weight decay is set to 0.0005; and the training batch size
(i.e. the number of samples per training batch) is set to 256.
Additionally, in order to facilitate the evaluation of vari-
able parameters, we set each parameter a default value: the
distance threshold is set to 0.7; the group element threshold
nCGF is set to 5; the non-zero element threshold nISR is set
to 800; the hidden layer number and parameters per layer
of the DNN classifier are set to 4 and 8192, respectively.
Evaluation metrics
For all the evaluations in our experiments, we randomly se-
lect 90% (2810) samples for training, and the rest 10% (312)
Fig. 2 Flowchart of the Indexed Sparsity Reduction (ISR) step. After indexing of the non-zero elements, if nNZ≥ nISR, select the top nISR non-zero elements
that have the highest occurrence frequency; if nNZ< nISR, we conduct zero-padding to the tail of the output data so that it has the length of nISR
Table 2 Workflow of DNN classifier
Input: Gene data matrix A ∈ {0, 1}m × n after CGF and ISR, where rows
and columns correspond to samples and genes, respectively; max
training epoch Emax.
1: Training: for each training epoch e ≤ Emax:
(a) For each sample ai = A(i, :):
i. Conduct feed-forwarding and compute the loss J;
ii. Conduct back-propagation to update the W and b
2: Testing: for each sample ai = A(i, :):
(a) Conduct feed-forwarding and get softmax probability P;
(b) Adopt the cancer type correspond to max(P) as the result of ai.
Output: Trained network model (training) or classification results for the
samples (testing).
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samples for testing. In parameter optimization steps for
DeepGene, we adopt the 10-fold cross validation accuracy
on the training set as the evaluation metric; on the other
hand, in the comparison with widely adopted models, we
adopt the testing accuracy as the evaluation metric.
Implementation
The CGF and ISR steps are implemented by original
coding in MATLAB, while the DNN classifier is
implemented on the MatConvNet toolbox [42], which is
a MATLAB-based convolutional neural network (CNN)
toolbox with various extensibilities.
Evaluation of design options
Determination of CGF’s variable
There are two variables that need to be experimentally
determined for the CGF step, namely the distance
threshold dCGF and the group element threshold nCGF.
Table 3 Sample and mutation statistics of the TCGA-DeepGene dataset on 12 cancer types




ACC 91 6741 501 15 368 2534 344 42 10,545
BLCA 130 24,067 2142 46 0 9662 528 55 36,500
BRCA 992 55,063 4841 133 3998 17,901 1424 0 83,360
CESC 194 26,606 2716 84 5595 9765 527 0 45,293
HNSC 279 31,416 2545 44 0 12,149 776 0 46,930
KIRP 171 8910 499 17 394 3411 524 0 13,755
LGG 284 5341 378 7 102 2074 294 0 8196
LUAD 230 44,800 3477 46 0 15,594 1377 99 65,393
PAAD 146 21,067 1496 19 859 7936 1005 111 32,493
PRAD 261 9628 563 15 652 3750 513 55 15,176
STAD 288 82,265 4200 92 48 33,344 1868 227 122,044
UCS 56 3070 187 2 234 1114 171 0 4778
Total 3122 318,974 23,545 520 12,250 119,234 9351 589 484,463
Table 4 10-fold cross validation accuracies (%) of DeepGene with different nCGF (row) and dCGF (column)
The optimal result is marked in red. Mean accuracy: 53.0%; standard deviation: 5.01%; maximum accuracy: 63.9%; minimum accuracy: 38.9%. The corresponding
3D bar-plot is shown in Fig. 3a for sensitivity review
The Author(s) BMC Bioinformatics 2016, 17(Suppl 17):476 Page 248 of 303
To determine the two variables, we change them in 2-
dimensional manner, while keeping all the other vari-
ables the default values as described in the “Constant
parameters” Section. The corresponding 10-fold cross
validation accuracies are listed in Table 4, and the
corresponding 3D bar-plot to present sensitivity is
shown in Fig. 3a. We adopt dCGF = 0.7 and nCGF = 5
for the following experiments based on the observed
experimental results, since they contribute to the
optimal performance.
Determination of ISR’s variable
The non-zero element threshold nISR needs to be experi-
mentally determined for the ISR step. We monitor the
number of non-zero elements for each sample in the
dataset, and plot the corresponding histogram in Fig. 4.
It is seen that 3030 (or more than 97%) of the 3122 sam-
ples have less than 800 non-zero genes among the total
22,834 genes. We thus adopt nISR = 800, which not only
concentrates the data to the non-zero elements, but also
greatly shrinks the data length.
Fig. 3 3D bar-plots of parameter estimations for sensitivity review. The Z-axis stands for 10-fold cross validation accuracy. a Parameter estimation
for dCGF and nCGF, corresponding to Table 4; b parameter estimation for layer number and parameter number per layer for the DNN classifier,
corresponding to Table 5; c parameter estimation for cost and gamma for SVM, corresponding to Table 6; d parameter estimation for Table 7
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Determine the network architecture
We also need to determine the network architecture for the
DNN classifier, which involves two variables: the hidden
layer number (#layer) and the parameter number per layer
(#param). Enlightened by [43], we monitor the classifier’s
10-fold cross validation accuracy with various hidden layer
numbers and parameter numbers, the results of which are
listed in Table 5, and the corresponding 3D bar-plot to
present sensitivity is shown in Fig. 3b. We see that the per-
formance reaches optimal at #layer = 4 and #param= 8192.
These values are thus adopted in our following experiments.
Evaluate the effect of combining CGF and ISR
After determining the related parameters for the three
steps of DeepGene, we evaluate the impact of our two
major innovations, i.e. CGF and ISR. It is mentionable that
we conduct CGF and ISR separately and concatenate their
results (as shown in Fig. 1) instead of conducting them
consecutively. The reason is that the outputs of CGF and
ISR are binary data and index data, respectively. Consecu-
tive conduction will only leave the index data (from ISR),
while separate conduction can benefit from both the bin-
ary data and the index data, thus introduces less bias.
Based on Fig. 1, we compare the performances of the
DNN classifier with different configurations:
(1)CGF and ISR (i.e. the proposed input structure);
(2)Only CGF (the upper half of Fig. 1);
(3)Only ISR (the lower half of Fig. 1);
(4)Neither CGF nor ISR (use the raw gene data instead).
Fig. 4 Non-zero element distribution of the gene samples in the TCGA-DeepGene dataset. Ninety-seven percent of all the 3122 samples have no
more than 800 non-zero gene elements
Table 5 10-fold cross validation accuracies (%) of DeepGene with different #layer (row) and #param (column)
The optimal result is marked in red. Mean accuracy: 57.9%; standard deviation: 3.42%; maximum accuracy: 64.0%; minimum accuracy: 53.2%. The corresponding
3D bar-plot is shown in Fig. 3b for sensitivity review
The Author(s) BMC Bioinformatics 2016, 17(Suppl 17):476 Page 250 of 303
The 10-fold cross validation results are shown in Fig. 5.
It is clearly observed that the complete CGF + ISR out-
performs both CGF and ISR when conducted alone, and
also significantly outperforms the raw data without any
pre-processing.
Comparison with widely adopted models
We then select three most representative data classifiers
that are commonly used in SMCC as comparison
methods, namely Support Vector Machine (SVM) [28],
k-Nearest Neighbors (KNN) [44] and Naïve Bayes (NB)
[45]. In order to exhibit the pre-processing effect of CGF
and ISR, all the comparison methods use raw gene data
as inputs. The three methods are set up as below.
SVM: we use the LIBSVM toolbox [46] in implementing
the SVM. Based on the results of a previous work for gene
classification [26], the kernel type (−t) is set to 0 (linear ker-
nel). Note that due to the feature set is high dimensional,
the linear kernel is suggested over the RBF (Gaussian) ker-
nel [46]; this suggestion is consistent to our trial and error
experience on this problem. A 10-fold cross validation is
conducted to optimize the parameters cost (−c) and gamma
(−g), and the other parameters are set as their default values.
The cross validation results are shown in Table 6, and the
corresponding 3D bar-plot to present sensitivity is shown in
Fig. 3c. We adopt 22 = 4 and 2‐ 5 = 0.0313 for -c and -g, re-
spectively, which lead to the best results in Table 6.
KNN: we compare the performances of Euclidean dis-
tance and Pearson correlation coefficient, which are the
two most commonly used similarity measures in gene
data analysis [26]. The 10-fold cross validation results of
the two similarity measures with different neighborhood
numbers are shown in Table 7, and the corresponding
3D bar-plot to present sensitivity is shown in Fig. 3d.
We adopt the Pearson correlation coefficient and set the
neighborhood number to 4, which lead to the optimal
validation accuracy.
NB: following [47], the average percentage of non-zero
elements in the samples of each cancer category is set as
the prior probability.
In the performance comparison between different
models, the testing accuracy is adopted as the evaluation
metric (see the “Evaluation metrics” Section), which is
generally slightly lower than the 10-fold validation accur-
acy of the corresponding model. The experiment results
are plotted in Fig. 6. DeepGene shows significant advan-
tage against all the three comparison methods. The per-
formance improvements are 24.3% (65.5% vs. 52.7%),
60.5% (65.5% vs. 40.8%) and 710% (65.5% vs. 9.23%)
against SVM, KNN and NB, respectively. To further val-
idate the performance of the DNN classifier itself with-
out CGF and ISR, we also record the accuracy of the
DNN classifier with raw gene data, which is the same in-
put as the comparison methods. The results are shown
in Fig. 7, in which the DNN classifier still has the
Fig. 5 10-fold cross validation accuracy of DeepGene with different design options. Performance comparison of the complete DeepGene input
structure (CGF + ISR), CGF only, ISR only and raw gene data. The complete DeepGene shows significant advantage against the other
three options
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The main purpose of the CGF step is to filter out irrele-
vant genes in the samples and locate the candidate dis-
criminatory gene subset. It first groups the genes based
on popularity (mutation occurrence frequency) and
inter-sample similarity, and then selects the top genes in
each group, and finally unites all the genes selected as
the output.
The two required parameters, dCGF and nCGF, are ex-
perimentally determined (as shown in Table 4). The two
adopted values, dCGF = 0.7 and nCGF = 5, are in the mid-
stream of the evaluation ranges, which are more reliable
than the marginal values.
By comparing the performances of the CGF against
raw gene data, as the second and fourth bars in Fig. 5 in-
dicate, the CGF has exhibited significant performance
boosting. It raises the validation accuracy by 4.25% (from
61.2 to 63.8%), and also contributes to the high perform-
ance of the combined CGF + ISR input structure. The
advantage of CGF lies in its ability to mask out the ma-
jority of irrelevant genes, thus maximally suppress their
negative influence, and only focus the data to the dis-
criminatory gene subset.
Indexed sparsity reduction
The ISR step is meant to reduce the data sparsity by
converting the gene data into the indexes of its non-zero
elements. In that case only the non-zero elements’ infor-
mation is left, while all the zero elements are discarded.
The data sparsity will thus be tremendously reduced,
making the subsequent classifier only focus on the in-
formative non-zero elements.
The required parameter nISR is experimentally deter-
mined. We monitor the non-zero element distribution
among all of the 3122 samples in the TCGA-DeepGene
dataset, and record the non-zero element range of each
sample. Figure 4 indicates that 97% of the samples have
no more than 800 non-zero elements (which are only
3.5% of the total 22,834 genes per sample). We thus set
nISR = 800, which is able to reduce the majority of the
data sparsity while maximally reserving the discrimin-
atory information of the samples.
Like CGF, ISR has exhibited significant contribution in
improving the performance of our classifier, as the third
bar in Fig. 5 indicates. It raises the accuracy against raw
gene data by 6.05% (from 61.2 to 64.9%), which is even
Table 7 10-fold cross validation accuracies (%) of KNN with different similarity measures (row) and neighborhood numbers (column)
The optimal result is marked in red. Mean accuracy: 35.3%; standard deviation: 5.63%; maximum accuracy: 43.6%; minimum accuracy: 28.2%. The corresponding
3D bar-plot is shown in Fig. 3d for sensitivity review
Table 6 10-fold cross validation accuracy (%) of SVM with different cost (row) and gamma (column) parameters
The optimal result is marked in red. Mean accuracy: 46.6%; standard deviation: 3.97%; maximum accuracy: 55.4%; minimum accuracy: 37.6%. The corresponding
3D bar-plot is shown in Fig. 3c for sensitivity review
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Fig. 6 Testing accuracy of DeepGene against three widely adopted classifiers. DeepGene is clearly advantageous to the comparison methods
Fig. 7 Testing accuracy of DeepGene against three widely adopted classifiers with raw gene input data. All methods use raw gene data as input.
The DNN classifier is still favorable against the other methods
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more significant than what the CGF contributes. We attri-
bute ISR’s advantage to its remarkable reduction of the
gene data sparsity. It is also mentionable that ISR exhibits
more strength when combined with CGF, as the first bar
in Fig. 5 indicates. This can be explained by the synergy
effect of binary gene data and indexed gene data.
Furthermore, we note that ISR conducts lossless con-
version when nNZ ≤ nISR, i.e. the indexed data can be
readily converted back to the original binary data if
necessary.
Data optimization by CGF and ISR
Besides aiding our DeepGene method, the CGF and ISR
steps can also benefit other classification methods for in-
put data optimization. To evaluate the optimization ef-
fect, we apply CGF + ISR to the three classifiers SVM,
KNN and NB discussed in the “Comparison with widely
adopted models” Section, and record their testing accur-
acies before and after the input data optimization. For
fair comparison, the parameters of the classifiers remain
the same.
Figure 8 shows the accuracy change before and after
the input data optimization of CGF + ISR. It is observed
that applying CGF + ISR can notably refine the input
data, thus improve the testing accuracies of the classi-
fiers. We also note that by applying CGF + ISR, the
accuracy improvements of the three classifiers are not
as large as that of DeepGene. Since DeepGene is
based on DNN, it is more advantageous in processing
complicated data structures, thus can benefit from
CGF + ISR more.
DNN classifier
The DNN classifier is the mainstay of DeepGene, which
conducts the classification and generates the final output.
Figure 6 has shown the significant advantage of DeepGene
against three widely adopted classifiers, among which
DeepGene exhibits at least 24% of performance improve-
ment. To examine the performance of the DNN classifier
itself without the pre-processing steps of CGF and ISR, we
also record the accuracy of the DNN classifier with raw
gene data in Fig. 7, which has shown that the DNN classi-
fier still generates the best accuracy (60.1% against the sec-
ond best 52.7% of SVM).
To further validate that the 10-fold validation accuracy
of DNN is indeed higher than that of SVM, we assume
that these two classifiers are independent of each other,
and conduct t-test with the null hypothesis that these
two classifiers have equal validation accuracy under the
significance of 0.001. The sample standard deviation of
DNN and SVM are recorded as sX1 ¼ 1:51% ¼ 0:0151
and sX2 ¼ 2:12% ¼ 0:0212, respectively. The t statistic is
then calculated as:
Fig. 8 Testing accuracies of three widely adopted classifiers with and without CGF + ISR for input data optimization. Applying CGF + ISR can
notably refine the input data, thus improve the testing accuracies of the classifiers
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Here, the degree of freedom is n − 1 = 9. By checking
the one-tailed significance table, the corresponding t
statistic of the p-value 0.001 is 3.922, which is far less
than our t = 488.5. Hence the null hypothesis is rejected
in favor of the alternative hypothesis, and we prove that
the 10-fold cross validation accuracy of DNN is indeed
higher than that of SVM. It is notable that using the
DNN alone is the lowest configuration of DeepGene (see
Fig. 5), and SVM has the highest performance out of the
three comparison classifiers. As a result, our t-test above
has also proved that DeepGene is indeed higher in per-
formance against all of the three comparison methods.
We attribute the advantage of the DNN classifier to its
capacity in extracting the complex features of the input
data. The multiple nonlinear processing layers make the
DNN especially suitable in processing complex data that
are too tough for conventional linear classifiers such as
linear kernel SVM. We also note that DeepGene is just
one of our initial trials for DNN-based gene data pro-
cessing, but has already shown promising results against
widely adopted methods. The DNN classifier has the po-
tential to show greater advantages towards more com-
plex (e.g. images or multi-dimensional gene data) and
large-scale data to conventional classifiers, which will be
discussed in our future works.
Limitation and future study
Currently DeepGene is only tested on datasets of som-
atic point mutations with known cancer types, i.e., the
histological biopsy sites are already known. Therefore, in
this study, DeepGene only demonstrates the power of
capturing complex association between somatic point
mutation and cancer types, and more of its application
potentials will be evidenced by tumor samples with com-
pletely unknown cancer type information (such as CTC
or ctDNA data) in our future works. The association be-
tween point mutation and other genetic aberrations such
as copy number variance, translocation, and small inser-
tion and deletion will also be covered in our future
works. It will be proved that to a large extent, adopting
point mutation alone is good enough for cancer type or
subtype classification.
Conclusions
In this paper, we propose the DeepGene method for
somatic point mutation based cancer type classification.
DeepGene consists of three major steps. The CGF step
concentrates the gene data with mutation occurrence
frequency; the ISR step reduces the gene data sparsity
with the indexes of non-zero elements; and in the final
step, the DNN-based classifier takes the processed data
and generates the classification result with high-level
data feature learning.
We conduct experiments on the compiled TCGA-
DeepGene dataset, which is a reformulated subset of the
TCGA dataset with mutations on 12 types of cancer.
Controlled variable experiments indicate that CGF, ISR
and DNN classifier all have significant contribution in
improving the classification accuracy. We then compare
DeepGene with three widely adopted data classifiers, the
results of which exhibit the remarkable advantages of
DeepGene, which has achieved > 24% of performance
improvement in terms of testing accuracy against the
comparison classification methods.
We demonstrated the advantages and potentials of the
DeepGene model for somatic point mutation based gene
data processing, and we suggest that the model can be
extended and transferred to other complex genotype-
phenotype association studies, which we believe will
benefit many related areas. As for future studies, we will
refine our model for other complex and large-scale data,
as well as broadening our training dataset, so that the
classification result can be further improved.
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